X

Trial Profile

TOP: TYSABRI Observational Program

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Natalizumab (Primary)
Indications Multiple sclerosis
Focus Adverse reactions
Acronyms TOP
Sponsors Biogen

Most Recent Events

15 Feb 2024 Status changed from active, no longer recruiting to completed.
22 Apr 2021 Results of an analysis assessing the conversion to non-active Secondary Progressive Multiple Sclerosis in patients with relapsing-remitting multiple sclerosis who discontinued or remained on Natalizumab presented at the 73rd Annual Meeting of the American Academy of Neurology
26 May 2020 Results (n=6484) presented at the 6th Congress of the European Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com